Valuation: Hemogenyx Pharmaceuticals Plc

Market Cap 42.09M 55.59M 49.67M 46.34M 79.27M 5.38B 79.87M 557M 218M 2.73B 209M 204M 8.79B P/E 2024
-2.38x
P/E 2025 -2.6x
Enterprise Value 42.51M 56.14M 50.16M 46.8M 80.06M 5.43B 80.66M 562M 220M 2.76B 211M 206M 8.88B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
70.98%
Yield 2024 *
-
Yield 2025 -
1 day-10.29%
1 week+29.77%
Current month+29.77%
1 month+23.18%
3 months-21.65%
6 months-34.50%
Current year+8.22%
1 week 460.5
Extreme 460.5
800
1 month 430
Extreme 430
800
Current year 430
Extreme 430
1,220
1 year 356
Extreme 356
1,329.35
3 years 124
Extreme 124
2,853.6
5 years 124
Extreme 124
2,853.6
10 years 124
Extreme 124
6,155
Manager TitleAgeSince
Chief Executive Officer 61 03/10/2017
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 03/10/2017
Director/Board Member - 03/10/2017
Director/Board Member 78 03/10/2017
Date Insider Type Main position Quantity % Market Cap. Importance
29/05/26 Free

Director

300,000 4.4118%
29/05/26 Free

Founder

300,000 4.4118%
29/05/26 Free

Founder

300,000 4.4118%
Change 5-day change 1-year change 3-year change Capi.($)
-10.29%+29.77%-52.02%-29.66% 62.31M
+4.16%+4.16%+49.37%+94.17% 74.69B
+0.46%-0.97%+23.51%+79.34% 58.81B
+0.17%+0.35%+6.85%+34.55% 48.45B
+0.50%-2.14%+331.33%+702.20% 42.84B
-0.72%-3.99%+28.50%+29.94% 42.79B
+0.34%-0.52%+6.56%+109.35% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-0.50%-3.10%-10.19%-14.35% 24.05B
-3.32%-10.86%-37.32%+316.28% 22.98B
Average -0.93%+0.84%+35.58%+137.45% 38.71B
Weighted average by Cap. +0.67%-1.79%+52.36%+149.35%

Financials

2024 2025
Net sales - -
Net income -5.62M -7.42M -6.63M -6.19M -10.58M -718M -10.66M -74.34M -29.04M -365M -27.86M -27.26M -1.17B -9.76M -12.89M -11.52M -10.75M -18.38M -1.25B -18.52M -129M -50.45M -634M -48.39M -47.35M -2.04B
Net Debt 2.46M 3.25M 2.91M 2.71M 4.64M 315M 4.67M 32.6M 12.73M 160M 12.22M 11.95M 515M 418K 552K 493K 460K 787K 53.38M 793K 5.53M 2.16M 27.15M 2.07M 2.03M 87.27M
Projected Income Statement - Annual - Hemogenyx Pharmaceuticals Plc
Logo Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Employees
16
Date Price Change Volume
07/10/26 GBX 619.00 -10.29% 28,456
06/10/26 GBX 690.00 -1.43% 31,791
05/10/26 GBX 700.00 +7.69% 46,950
02/10/26 GBX 650.00 +20.37% 93,639
01/10/26 GBX 540.00 +13.21% 23,518
  1. Stock Market
  2. Stocks
  3. HEMO Stock